<DOC>
	<DOCNO>NCT02853994</DOCNO>
	<brief_summary>The study prospective , non-randomized , multicenter , post-marketing surveillance study evaluate CE-marked DEVOIR Sirolimus-Coated Coronary Balloon 4 subgroup regard device approve indication : - In-stent restenosis lesion : either bare metal drug elute stent restenosis - Bifurcation lesion ( drug-eluting stent main branch drug-coated balloon side branch ) : treatment lesion Medina type except ( 0,0,1 ) native coronary artery - Small vessel : treatment lesion â‰¤2.75 mm - BMS implantation follow DCB inflation</brief_summary>
	<brief_title>Safety Efficacy DEVOIR Sirolimus-Coated Coronary Balloon Real-world Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patient 's inclusion exclusion criterion per device instruction use 's indication contraindication . Inclusion criterion : 1 . Patient least 18 year old 2 . Lesion lengths range 8 38 mm diameter range 1.50 mm 4.00 mm . Exclusion criterion : 1 . Patients hypersensitivity Sirolimus drug structural activity relate compound . 2 . Patients know hypersensitivity excipients phospholipid related origin . 3 . Patients whose diseased segment predilated prepared drug coat balloon treatment . 4 . Severely calcified lesion require treatment type e.g . Rotational Atherectomy ( Rotablator ) 5 . Patients judged lesion prevents complete inflation angioplasty balloon proper placement delivery catheter 6 . Patients receive recommend antiplatelet anticoagulation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>DCB</keyword>
	<keyword>DEB</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>PCI</keyword>
	<keyword>ISR</keyword>
	<keyword>SVD</keyword>
	<keyword>Restenosis</keyword>
	<keyword>Bifurcation</keyword>
	<keyword>CAD</keyword>
	<keyword>Coronary artery</keyword>
</DOC>